# SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate

- Link: https://www.thailand-business-news.com/pr-news/sk-bioscience-advances-development-of-next-generation-infectious-disease-prevention-platform-with-global-phase-1b-cta-submission-for-rsv-preventive-antibody-candidate
- Published: 2026-08-14T19:00:00+07:00
- Author: PR Newswire

|   |

 ◦ **Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately
   80 infants aged 2 weeks to 8 months**
 ◦ **Company expands its global portfolio beyond vaccines into antibody-based preventive
   technologies**
 ◦ **Growing global R&D network strengthens capabilities in next-generation infectious
   disease prevention**

INCHEON, South Korea, Aug. 14, 2026 /PRNewswire/ — SK bioscience announced that 
it has submitted a Clinical Trial Application (CTA) to the South African Health 
Products Regulatory Authority (SAHPRA) for a global pediatric Phase 1b clinical 
trial of RSM01, a respiratory syncytial virus (RSV) preventive antibody candidate
licensed from the Gates Medical Research Institute (Gates MRI), a nonprofit medical
research organization affiliated with the Gates Foundation.

The Phase 1b study will enroll approximately 80 infants aged 2 weeks to 8 months
and evaluate the safety and pharmacokinetic profile of RSM01. Through the study,
SK bioscience aims to assess the clinical development potential of RSM01 as an RSV
preventive antibody for infants and establish a foundation for subsequent late-stage
clinical development.

RSM01 is a preventive antibody candidate that SK bioscience secured through a licensing
agreement with Gates MRI in February 2026. Gates MRI conducted the candidate’s early-
stage research and Phase 1a clinical development in adults. The new Phase 1b study
marks an important step in expanding RSM01’s clinical development from adults to
infants, a key population targeted for RSV prevention.

RSV is a major respiratory virus that can cause severe lower respiratory tract infections
in infants and young children, with a particularly significant disease burden during
the first months of life. Because very young infants may have limitations in developing
sufficient active immunity through direct vaccination, preventive strategies that
provide immediate passive immunity through the administration of antibodies can 
play an important role. Against this backdrop, the development of antibody-based
approaches to RSV prevention continues to advance globally.

According to global market research firm Evaluate Pharma, the worldwide market for
RSV preventive antibodies is projected to reach USD 4.5 billion by 2032. With several
preventive antibodies already commercialized, primarily in developed markets, demand
for RSV prevention among infants and young children is expected to continue driving
market growth.

SK bioscience is expanding its respiratory disease prevention portfolio from cell-
culture influenza vaccines and pneumococcal vaccines into RSV antibody-based preventive
technologies. By building R&D capabilities spanning both vaccines and antibody-based
approaches, the company aims to address a broader range of unmet needs in infectious
disease prevention.

Jaeyong Ahn, CEO of SK bioscience, said, "Advancing this next-generation infectious
disease prevention technology, secured through a global partnership, into global
clinical development by combining it with our own R&D capabilities represents a 
meaningful milestone. We will continue to strengthen our ability to respond to global
infectious disease threats by securing and advancing diverse prevention platforms."

SK bioscience continues to expand its global R&D network through collaborations 
including the joint development of a pneumococcal vaccine with Sanofi, its RSV prevention
partnership with Gates MRI, and the introduction of injectable rotavirus vaccine
technology from the U.S. Centers for Disease Control and Prevention (CDC). Building
on these global partnerships, the company plans to further broaden its infectious
disease prevention portfolio.

**About SK bioscience **

[SK bioscience ](https://www.skbioscience.com/en/main)is an innovative vaccine and
biotech company, committed to vaccine development and manufacturing to enable more
equitable access to vaccines around the world. Leveraging strengths on cutting-edge
technologies, SK bioscience has been dedicated to promoting human health from prevention
to cure across the globe. With the cooperation of domestic and international governments,
regulatory agencies, healthcare providers, doctors, and medical experts, all of 
the SK colleagues are passionately committed to providing high-quality vaccines 
to those who need them and better public healthcare solutions.

**SK bioscience Communications Team**

Changhyun Jin ([jin99@sk.com](https://www.thailand-business-news.com/pr-news/jin99@sk.com))

Tae-Gyun Kim ([taegyunkim@sk.com](https://www.thailand-business-news.com/pr-news/taegyunkim@sk.com))
Moonchel Kim ([mc_kim@sk.com](https://www.thailand-business-news.com/pr-news/mc_kim@sk.com))

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate ](http://www.prnasia.com/story/archive/5026469_CN26469_0?rand=184833)
